Pfizer reports long-term safety of tamper-proof extended-release analgesic
This article was originally published in Scrip
Executive Summary
Pfizer has announced that top-line data from an open-label Phase III study has provided evidence of the long-term safety of its investigational analgesic, ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules), in patients with moderate-to-severe chronic, non-cancer pain.